In the search of new BTK reversible inhibitors with enhanced selectivity for the treatment of rheumatoid arthritis (RA), RN486 (Figure 5B) was developed and examined in in vitro binding and competition studies, as well as in cell-based assays (42). The gene discussed is BTK; the disease is rheumatoid arthritis.